Figure 3.
Association of PD-L1 expression with immunotherapy efficacy in NSCLC. (A) PFS and (B) OS curves for patients with PD-L1 TPS≥1% and <1%. (C) PFS and (D) OS curves for patients with PD-L1 TPS<1%, 1-49%, and ≥50%. TPS, tumor proportion score.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.